Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 29, 2012

Genentech, Ensemble Partner on Macrocyclic Drug Development

  • Roche’s Genentech established a collaboration with Ensemble Therapeutics focused on identifying macrocyclic Ensemblin™ drug candidates against specified Genentech targets. Under terms of the deal Genentech will have the right to develop and commercialize lead molecules in return for paying Ensemble an up-front fee, development milestones, and royalties on future sales of relevant products.

    Ensemble Therapeutics is leveraging its DNA-Programmed Chemistry™ (DPC™) platform to develop a class of synthetically engineered small molecule macrocyclic drugs known as Ensemblins, which it claims can address targets including protein-protein interactions, phosphatases, and proteases that aren’t accessible to conventional small molecule drugs. The firm is exploiting the technology both to develop an in-house pipeline of oral candidates against cancer and immuno-inflammatory diseases as well as through drug discovery partnerships.

    In-house R&D is focused largely on identifying Ensemblins that inhibit protein-protein or protein-peptide interactions. It is headed by a preclinical-stage interleukin-17 antagonist, which is in development as a potential candidate for treating inflammatory and autoimmune diseases. Ensemble has Ensemblin discovery and development partnerships ongoing with Bristol-Myers Squibb and Pfizer.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »